Bambuterol

Bambuterol

Clinical data
Pregnancy category	Unknown
Routes of administration	Oral
ATC code	R03CC12 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	20%
Metabolism	Hepatic, extensive Further metabolized to terbutaline by plasma cholinesterase
Elimination half-life	13 hours (bambuterol) 21 hours (terbutaline)
Excretion	Renal
Identifiers
IUPAC name {3-(dimethylcarbamoyloxy)-5-[1-hydroxy-2-(tert-butylamino) ethyl]phenyl} N,N-dimethylcarbamate
CAS Number	81732-46-9
PubChem CID	54766
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H29N3O5
Molar mass	367.44 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Bambuterol (INN, marketed by AstraZeneca under the trade names Bambec and Oxeol) is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.